Progression-Free Survival: Meaningful or Simply Measurable?
Author:
Affiliation:
1. NCIC Clinical Trials Group, Queen's University, Kingston, Ontario, Canada
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2011.38.7571
Reference39 articles.
1. Reporting results of cancer treatment
2. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
3. Evolution of the Randomized Controlled Trial in Oncology Over Three Decades
4. Randomized controlled trials (RCTs) in the era of molecular oncology: Methodology, biomarkers, and endpoints.
Cited by 261 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting;European Journal of Cancer;2024-01
2. Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis;Gynecologic Oncology;2023-12
3. Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs;Journal of Clinical Oncology;2023-11-10
4. Elucidating the Benefit of Radiation Therapy in GI Cancers: Rethinking Trial End Points and Patient Selection;Journal of Clinical Oncology;2023-10-19
5. Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials;Seminars in Radiation Oncology;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3